ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for treatment in 133 countries.

Experts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

In a session titled, Better meeting the needs of people living with HIV, health experts reminded us that science, care, and ...